Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong partnerships with J&J and Roche. The partnership model using ENHANZE tech mitigates risks, enhances operational efficiency, and offers partners a way to avoid patent cliffs, ensuring long-term growth. Despite strong near-term growth prospects, potential patent disputes and reliance on partnerships pose risks; vigilance is necessary to maintain Halozyme's growth stock status.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Announces Record Earnings, Guidance
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024.
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Helen Torley - President, Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Tram Bui - Vice President of Investor Relations, Corporate Communications Conference Call Participants Brendan Smith - TD Cowan Mike DiFiore - Evercore ISI Jason Butler - Citizens JMP Corinne Jenkins - Goldman Sachs Mitchell Kapoor - H.C. Wainwright Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Operator Good afternoon.
Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.75 per share a year ago.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside
Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited upside potential. This year, Halozyme's stock has surged by 50%, compared to the S&P 500's approximately 21% rise.
Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
